Retrospective studies show elevated risks, especially for glomerular or proteinuric kidney disease, but absolute risk remains ...

Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of ...

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Early Intervention: Flagging non-adherence allows for earlier intervention, such as a phone call. This compassionate, ...

Integration of targeted therapies and immunotherapies offers new hope, enhancing survival rates and quality of life. Patients with mantle cell lymphoma experienced better survival rates when treated ...

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...

ICHRAs could either stabilize or destabilize ACA risk pools, with adoption patterns raising concerns about access, equity, ...